TimesSquare Capital Management

TimesSquare US Small Cap Growth Strategy

US Small-cap Growth

Jun 2025 → Sep 2025

Our archive holds 2 letters from this strategy, behind 2 investment theses and positions in 16 companies. Every quote below is copied verbatim from the letter it came from.

2 letters in a year · follow all of TimesSquare Capital Management for every strategy.

What it bought and sold

  • In the near term, its shares gained 95% and we trimmed on that strength.
  • New positionUniFirst CorporationSep 2025
    During the quarter we began a position in UniFirst Corporation, which supplies a range of work clothing, uniforms, protective apparel, and facility service products.
  • New positionMirion TechnologiesSep 2025
    Joining the strategy this quarter was Mirion Technologies, which manufactures radiation detection, measurement, and monitoring products serving nuclear power and medical applications.
  • AddedSiTime CorporationSep 2025
    we bought additional shares.
  • We see both issues as transitory, knowing that Casella in the past quickly improved margins of acquisitions and the ERP system should facilitate that, so we added to our position.
  • ExitedVerona PharmaSep 2025
    In July, Merck announced plans to acquire this developer of treatments for allergic rhinitis and other chronic respiratory diseases, and we subsequently sold our shares.
  • As its shares pulled back by -14% we also reduced our holdings.
  • AddedSoleno TherapeuticsSep 2025
    We felt differently about biopharma developer Soleno Therapeutics and added to our holdings as its shares pulled back by -19%.
  • Those problems persisted, so we exited the position.
  • AddedPursuit AttractionsSep 2025
    We added to our position early in the quarter after Pursuit acquired a new property in Costa Rica, which tends to be a counter-cyclical market and seemed to be a good strategic fit.
  • New positionMirum PharmaceuticalsSep 2025
    New to the strategy this quarter was Mirum Pharmaceuticals, a commercial-stage biopharma developer of liver disease treatments.

Also held

Its investment theses

Every letter